Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression

Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with <em>RUNX3</em> overexpression

Anaplastic lymphoma kinase (ALK)- negative anaplastic large cell lymphoma (ALCL) is an aggressive CD30-positive non- Hodgkin lymphoma. ALK-ALCL rarely manifests with extensive bone marrow and peripheral blood involvement (known as “leukemic phase”). A 54-year-old woman was diagnosed with ALK-ALCL in...

Full description

Bibliographic Details
Main Authors: Yusuke Yamashita, Yoshikazu Hori, Hideki Kosako, Takehiro Oiwa, Kenji Warigaya, Toshiki Mushino, Shogo Murata, Masakazu Fujimoto, Akinori Nishikawa, Shin-ichi Murata, Takashi Sonoki, Shinobu Tamura
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Hematology Reports
Subjects:
ALK-negative anaplastic large cell lymphoma
Brentuximab vedotin
leukemic phase
RUNX3
Online Access:https://www.pagepress.org/journals/index.php/hr/article/view/8368

Internet

https://www.pagepress.org/journals/index.php/hr/article/view/8368

Similar Items